Palvella Therapeutics (PVLA) Stock News
$PVLA · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Palvella Therapeutics (PVLA) in the past 30 days. BORSA’s news read on PVLA is bullish at 71/100, −1 over 24 hours, based on 1 company event over the past 7 days. PVLA last closed at $132.91 on Oct 27, up 7.25% over five sessions and down 4.95% over the past month. Palvella Therapeutics’ next earnings report is scheduled for Thursday, Nov 5 before the open.
The wire on $PVLA
newest first · updated · direct subject stories onlyFDA granted priority review for Qtorin (rapamycin) for microcystic lymphatic malformations. Stock up 8.7% to $144.49. PDUFA date Feb. 28, 2027.
bullish 80 · impact 50The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Palvella Therapeutics (PVLA) stock: common questions
What is the latest Palvella Therapeutics stock news?
The highest-impact PVLA story BORSA published in the past 30 days:
· Palvella Gains After FDA Grants Priority Review for Qtorin